PR 61
Alternative Names: PR-61Latest Information Update: 28 Aug 2023
At a glance
- Originator TheraPten Biosciences
- Developer National Research Council Canada; TheraPten Biosciences
- Class Antineoplastics; Recombinant fusion proteins; Tumour suppressor proteins
- Mechanism of Action PTEN Phosphohydrolase Replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jul 2023 PR 61 is available for licensing as of 17 Jul 2023. http://www.therapten.com/pipeline.html
- 17 Jul 2023 Preclinical trials in Cancer in Canada (IV) (TheraPten Biosciences pipeline, July 2023)
- 17 Jul 2023 TheraPten Biosciences plans clinical trials for Cancer (TheraPten Biosciences pipeline, July 2023)